
Biocon Biologics gets EU approval for 2 drugs to treat bone cancer, osteoporosis and bone loss
Biocon Biologics, a subsidiary of Biocon, has received marketing authorisation from the European Commission for two biosimilar drugs—Vevzuo and Evfraxy, both versions of Denosumab. This approval allows the company to market these products across the …